Cargando…
Outcomes of Patients With Metastatic Differentiated Thyroid Cancer After Excellent Response to Treatment
BACKGROUND: To evaluate the outcomes in differentiated thyroid cancer (DTC) patients who achieved excellent response to initial treatment and developed distant metastasis during follow-up. METHODS: Thyroid cancer patients registered in Chang Gung Memorial Hospital thyroid cancer database between Jan...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273717/ https://www.ncbi.nlm.nih.gov/pubmed/35837311 http://dx.doi.org/10.3389/fendo.2022.923182 |
_version_ | 1784745139431800832 |
---|---|
author | Hsu, Chia-Jung Lai, Kun-Yu Lu, Yu-Ling Wu, Ming-Hsien Liu, Feng-Hsuan Lin, Shu-Fu |
author_facet | Hsu, Chia-Jung Lai, Kun-Yu Lu, Yu-Ling Wu, Ming-Hsien Liu, Feng-Hsuan Lin, Shu-Fu |
author_sort | Hsu, Chia-Jung |
collection | PubMed |
description | BACKGROUND: To evaluate the outcomes in differentiated thyroid cancer (DTC) patients who achieved excellent response to initial treatment and developed distant metastasis during follow-up. METHODS: Thyroid cancer patients registered in Chang Gung Memorial Hospital thyroid cancer database between January 1979 and December 2019 were assessed. RESULTS: Among 1053 DTC patients with excellent response to initial therapy, 14 (1.3%) patients developed metastatic disease during follow-up, including 6 males and 8 females with median age of 50.2 years [interquartile range (IQR), 39.9-53.7]. Nine (64.3%) patients had papillary cancer, four (28.6%) had follicular cancer, and one (7.1%) had Hürthle cell cancer. Most patients (92.9%) had stage I disease at diagnosis. The sites of metastasis were lung (71.4%), bone (7.1%), mediastinum (7.1%) and multiple sites (14.3%). With a median follow-up of 18.3 years (IQR, 14.8-23.8), 2 patients had disease-specific mortality. The 5- and 10-year disease-specific survival after the diagnosis of distant metastasis was 92% and 74%, respectively. Multiple sites of metastasis was associated with increased risk of mortality (P = 0.022). CONCLUSIONS: A small proportion of DTC patients with an excellence response to initial therapy developed distant metastasis during follow-up. Multiple organ distant metastases conferred a worse disease-specific survival. |
format | Online Article Text |
id | pubmed-9273717 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92737172022-07-13 Outcomes of Patients With Metastatic Differentiated Thyroid Cancer After Excellent Response to Treatment Hsu, Chia-Jung Lai, Kun-Yu Lu, Yu-Ling Wu, Ming-Hsien Liu, Feng-Hsuan Lin, Shu-Fu Front Endocrinol (Lausanne) Endocrinology BACKGROUND: To evaluate the outcomes in differentiated thyroid cancer (DTC) patients who achieved excellent response to initial treatment and developed distant metastasis during follow-up. METHODS: Thyroid cancer patients registered in Chang Gung Memorial Hospital thyroid cancer database between January 1979 and December 2019 were assessed. RESULTS: Among 1053 DTC patients with excellent response to initial therapy, 14 (1.3%) patients developed metastatic disease during follow-up, including 6 males and 8 females with median age of 50.2 years [interquartile range (IQR), 39.9-53.7]. Nine (64.3%) patients had papillary cancer, four (28.6%) had follicular cancer, and one (7.1%) had Hürthle cell cancer. Most patients (92.9%) had stage I disease at diagnosis. The sites of metastasis were lung (71.4%), bone (7.1%), mediastinum (7.1%) and multiple sites (14.3%). With a median follow-up of 18.3 years (IQR, 14.8-23.8), 2 patients had disease-specific mortality. The 5- and 10-year disease-specific survival after the diagnosis of distant metastasis was 92% and 74%, respectively. Multiple sites of metastasis was associated with increased risk of mortality (P = 0.022). CONCLUSIONS: A small proportion of DTC patients with an excellence response to initial therapy developed distant metastasis during follow-up. Multiple organ distant metastases conferred a worse disease-specific survival. Frontiers Media S.A. 2022-06-28 /pmc/articles/PMC9273717/ /pubmed/35837311 http://dx.doi.org/10.3389/fendo.2022.923182 Text en Copyright © 2022 Hsu, Lai, Lu, Wu, Liu and Lin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Hsu, Chia-Jung Lai, Kun-Yu Lu, Yu-Ling Wu, Ming-Hsien Liu, Feng-Hsuan Lin, Shu-Fu Outcomes of Patients With Metastatic Differentiated Thyroid Cancer After Excellent Response to Treatment |
title | Outcomes of Patients With Metastatic Differentiated Thyroid Cancer After Excellent Response to Treatment |
title_full | Outcomes of Patients With Metastatic Differentiated Thyroid Cancer After Excellent Response to Treatment |
title_fullStr | Outcomes of Patients With Metastatic Differentiated Thyroid Cancer After Excellent Response to Treatment |
title_full_unstemmed | Outcomes of Patients With Metastatic Differentiated Thyroid Cancer After Excellent Response to Treatment |
title_short | Outcomes of Patients With Metastatic Differentiated Thyroid Cancer After Excellent Response to Treatment |
title_sort | outcomes of patients with metastatic differentiated thyroid cancer after excellent response to treatment |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273717/ https://www.ncbi.nlm.nih.gov/pubmed/35837311 http://dx.doi.org/10.3389/fendo.2022.923182 |
work_keys_str_mv | AT hsuchiajung outcomesofpatientswithmetastaticdifferentiatedthyroidcancerafterexcellentresponsetotreatment AT laikunyu outcomesofpatientswithmetastaticdifferentiatedthyroidcancerafterexcellentresponsetotreatment AT luyuling outcomesofpatientswithmetastaticdifferentiatedthyroidcancerafterexcellentresponsetotreatment AT wuminghsien outcomesofpatientswithmetastaticdifferentiatedthyroidcancerafterexcellentresponsetotreatment AT liufenghsuan outcomesofpatientswithmetastaticdifferentiatedthyroidcancerafterexcellentresponsetotreatment AT linshufu outcomesofpatientswithmetastaticdifferentiatedthyroidcancerafterexcellentresponsetotreatment |